Patents by Inventor Karl Jansson
Karl Jansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939349Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: GrantFiled: July 20, 2022Date of Patent: March 26, 2024Assignee: GALECTO BIOTECH ABInventors: Fredrik Zetterberg, Kristoffer Peterson, Karl Jansson
-
Publication number: 20220380401Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: ApplicationFiled: July 20, 2022Publication date: December 1, 2022Applicant: GALECTO BIOTECH ABInventors: Fredrik ZETTERBERG, Kristoffer PETERSON, Karl JANSSON
-
Patent number: 11447517Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: GrantFiled: November 15, 2019Date of Patent: September 20, 2022Assignee: GALECTO BIOTECH ABInventors: Fredrik Zetterberg, Kristoffer Peterson, Karl Jansson
-
Publication number: 20220017558Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: ApplicationFiled: November 15, 2019Publication date: January 20, 2022Applicant: GALECTO BIOTECH ABInventors: Fredrik ZETTERBERG, Kristoffer PETERSON, Karl JANSSON
-
Publication number: 20210380624Abstract: A compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: ApplicationFiled: October 9, 2019Publication date: December 9, 2021Applicant: GALECTO BIOTECH ABInventors: Fredrik ZETTERBERG, Ulf NILSSON, Thomas BRIMERT, Kristoffer PETERSON, Karl JANSSON
-
Patent number: 9340307Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: GrantFiled: September 20, 2013Date of Patent: May 17, 2016Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Patent number: 8754104Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: GrantFiled: November 6, 2012Date of Patent: June 17, 2014Assignee: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wannman, Anders Bjork
-
Publication number: 20140024678Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5- chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4 -hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4 -dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4 -tetrahydro-quinoline-3-carboxamide.Type: ApplicationFiled: September 20, 2013Publication date: January 23, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Patent number: 8545885Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: GrantFiled: May 14, 2012Date of Patent: October 1, 2013Assignees: Teva Pharmaceutical Industries, Ltd., Active Biotech, ABInventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Patent number: 8446158Abstract: An apparatus for converting a capacitance measured on a capacitive sensor to a digital code may include a modulation capacitor to receive charge transferred from the sensor and compensation circuitry to divert charge from the modulation capacitor. A method for operating the apparatus may include generating a digital bitstream based on the capacitance of the sensor and compensating for a parasitic capacitance of the capacitive sensor.Type: GrantFiled: November 7, 2008Date of Patent: May 21, 2013Assignee: Cypress Semiconductor CorporationInventor: Håkan Karl Jansson
-
Patent number: 8314124Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: GrantFiled: March 17, 2009Date of Patent: November 20, 2012Assignee: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wännman, Anders Björk
-
Publication number: 20120225124Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Patent number: 8178127Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: GrantFiled: December 19, 2008Date of Patent: May 15, 2012Assignee: Teva Pharmaceuticals Industries, Ltd.Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Publication number: 20090232889Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: ApplicationFiled: March 17, 2009Publication date: September 17, 2009Applicant: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wannman, Anders Bjork
-
Patent number: 7589208Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: GrantFiled: February 4, 2005Date of Patent: September 15, 2009Assignee: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wännman, Anders Björk
-
Patent number: 7560557Abstract: A process for the preparation of the compounds of general formula (I) wherein R is selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.Type: GrantFiled: March 21, 2005Date of Patent: July 14, 2009Assignee: Active Biotech AGInventor: Karl Jansson
-
Patent number: 7553849Abstract: A compound of formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R? is hydrogen, C1-C4 alkyl, C1-C3 alkoxy; halogen, trifluoromethyl or OCHxFy, R? is hydrogen, fluoro or chloro, that R? being fluoro or chloro only when R? is fluoro or chloro; R3 is hydrogen or C1-C5 alkyl R4 is hydrogen, CH2OCOC(CH3)3, pharmaceutically acceptable inorganic or organic cations, or COR4? wherein R4? is C1-C5 alkyl, phenyl, benzyl or phenethyl; R7 is methyl or ethyl; one of A and B is sulphur and the other is C-R2; when A is S, R2 is selected from hydrogen and methyl, with the proviso that R2 is methyl only when R3 is not hydrogen; and when B is S, R2 is hydrogen; and any tautomer thereof. A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.Type: GrantFiled: June 15, 2005Date of Patent: June 30, 2009Assignee: Active Biotech ABInventors: Anders Björk, Karl Jansson
-
Publication number: 20090162432Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid,1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: ApplicationFiled: December 19, 2008Publication date: June 25, 2009Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Patent number: 7511143Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.Type: GrantFiled: February 4, 2005Date of Patent: March 31, 2009Assignee: Active Biotech ABInventors: Karl Jansson, Tomas Fristedt, Hans Wännman, Anders Björk
-
Publication number: 20060004038Abstract: A compound of formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R? is hydrogen, C1-C4 alkyl, C1-C3 alkoxy; halogen, trifluoromethyl or OCHxFy, R? is hydrogen, fluoro or chloro, that R? being fluoro or chloro only when R? is fluoro or chloro; R3 is hydrogen or C1-C5 alkyl R4 is hydrogen, CH2OCOC(CH3)3, pharmaceutically acceptable inorganic or organic cations, or COR4? wherein R4? is C1-C5 alkyl, phenyl, benzyl or phenethyl; R7 is methyl or ethyl; one of A and B is sulphur and the other is C—R2; when A is S, R2 is selected from hydrogen and methyl, with the proviso that R2 is methyl only when R3 is not hydrogen; and when B is S, R2 is hydrogen; and any tautomer thereof. A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.Type: ApplicationFiled: June 15, 2005Publication date: January 5, 2006Applicant: ACTIVE BIOTECH ABInventors: Anders Bjork, Karl Jansson